In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Hims & Hers Health (HIMS – Research Report), with a price target of $10.25. The company’s shares closed yesterday at $10.25.
According to TipRanks, Singh is an analyst with an average return of -12.3% and a 37.72% success rate. Singh covers the Healthcare sector, focusing on stocks such as R1 RCM, Icon, and Evolent Health.
In addition to Truist Financial, Hims & Hers Health also received a Hold from Piper Sandler’s Korinne Wolfmeyer in a report issued today. However, on the same day, Citi maintained a Buy rating on Hims & Hers Health (NYSE: HIMS).
See today’s best-performing stocks on TipRanks >>
HIMS market cap is currently $2.02B and has a P/E ratio of -90.63.
Based on the recent corporate insider activity of 124 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HIMS in relation to earlier this year. Last month, Melissa Baird, the COO of HIMS bought 93,000.00 shares for a total of $186,999.48.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hims & Hers Health (HIMS) Company Description:
Oaktree Acquisition Corp. is an emerging growth company, which engages in the provision of merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded by Patrick McCaney, Alexander Taubman and Mathew Pendo in 2019 and is headquartered in Los Angeles, CA.
Read More on HIMS:
